{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T14:24:21Z","timestamp":1754144661113,"version":"3.41.2"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.pharep.2019.01.014","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T22:51:05Z","timestamp":1548975065000},"page":"417-421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["The effect of atorvastatin on cardiometabolic risk factors in women with non-classic congenital adrenal hyperplasia: A pilot study"],"prefix":"10.1007","volume":"71","author":[{"given":"Robert","family":"Krysiak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolina","family":"Kowalcze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Bednarska-Czerwi\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogus\u0142aw","family":"Okopie\u0144","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"10.1016\/j.pharep.2019.01.014_bib0005","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/MED.0000000000000402","article-title":"Update on diagnosis and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"25","author":"White","year":"2018","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.pharep.2019.01.014_bib0010","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/S0140-6736(17)31431-9","article-title":"Congenital adrenal hyperplasia","volume":"390","author":"El-Maouche","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.pharep.2019.01.014_bib0015","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11154-008-9097-x","article-title":"Non-classic adrenal hyperplasia","volume":"10","author":"Speiser","year":"2009","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.pharep.2019.01.014_bib0020","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/humupd\/dmx014","article-title":"Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women","volume":"23","author":"Carmina","year":"2017","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.pharep.2019.01.014_bib0025","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.steroids.2013.04.010","article-title":"Non-classic congenital adrenal hyperplasia","volume":"78","author":"Witchel","year":"2013","journal-title":"Steroids"},{"issue":"Suppl. 3","key":"10.1016\/j.pharep.2019.01.014_bib0030","first-page":"451","article-title":"Non-classic congenital adrenal hyperplasia","volume":"3","author":"Kelestimur","year":"2006","journal-title":"Pediatr Endocrinol Rev"},{"key":"10.1016\/j.pharep.2019.01.014_bib0035","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1055\/s-0033-1355383","article-title":"The effect of simvastatin treatment on plasma steroid levels in females with non-classic congenital adrenal hyperplasia","volume":"121","author":"Krysiak","year":"2013","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.pharep.2019.01.014_bib0040","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1055\/s-0035-1569375","article-title":"The effect of simvastatin on plasma steroid hormone levels in metformin-treated women with non-classic congenital adrenal hyperplasia","volume":"124","author":"Krysiak","year":"2016","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.pharep.2019.01.014_bib0045","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1055\/s-0034-1382048","article-title":"The effect of metformin on androgen production in diabetic women with non-classic congenital adrenal hyperplasia","volume":"122","author":"Krysiak","year":"2014","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.pharep.2019.01.014_bib0050","doi-asserted-by":"crossref","first-page":"852","DOI":"10.2174\/138161211795428849","article-title":"Lipid management for the prevention of cardiovascular disease","volume":"17","author":"Schaefer","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.pharep.2019.01.014_bib0055","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/HCR.0b013e318192754e","article-title":"A review of lipid management in primary and secondary prevention","volume":"29","author":"Dembowski","year":"2009","journal-title":"J Cardiopulm Rehabil Prev"},{"key":"10.1016\/j.pharep.2019.01.014_bib0060","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.coph.2013.01.004","article-title":"Anti-atherosclerotic mechanisms of statin therapy","volume":"13","author":"Babelova","year":"2013","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.pharep.2019.01.014_bib0065","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.atherosclerosis.2008.08.022","article-title":"The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis","volume":"203","author":"Blum","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharep.2019.01.014_bib0070","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.2165\/00003495-200363170-00005","article-title":"Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes","volume":"63","author":"Krysiak","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.pharep.2019.01.014_bib0075","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"New Engl J Med"},{"key":"10.1016\/j.pharep.2019.01.014_bib0080","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pharep.2019.01.014_bib0085","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2265.2009.03690.x","article-title":"Unfavourable trends in cardiovascular and metabolic risk in paediatric and adult patients with congenital adrenal hyperplasia?","volume":"73","author":"Mooij","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.pharep.2019.01.014_bib0090","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1210\/JC.2015-2093","article-title":"Increased cardiovascular and metabolic morbidity in patients with 21-hydroxylase deficiency: a Swedish Population-Based National Cohort Study","volume":"100","author":"Falhammar","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharep.2019.01.014_bib0095","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1590\/2359-3997000000119","article-title":"Cardiovascular risk factors and increased carotid intima-media thickness in young patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"59","author":"Rodrigues","year":"2015","journal-title":"Arch Endocrinol Metab"},{"key":"10.1016\/j.pharep.2019.01.014_bib0100","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra0800885","article-title":"Uric acid and cardiovascular risk","volume":"359","author":"Feig","year":"2008","journal-title":"N Engl J Med"},{"issue":"12 Pt. 2","key":"10.1016\/j.pharep.2019.01.014_bib0105","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.1301\/nr.2007.dec.S253-S259","article-title":"Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity","volume":"65","author":"Ridker","year":"2007","journal-title":"Nutr Rev"},{"key":"10.1016\/j.pharep.2019.01.014_bib0110","doi-asserted-by":"crossref","first-page":"2P","DOI":"10.1016\/j.amjcard.2006.09.014","article-title":"Inflammatory biomarkers in stable atherosclerosis","volume":"98","author":"Kinlay","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharep.2019.01.014_bib0115","doi-asserted-by":"crossref","first-page":"1563S","DOI":"10.1093\/ajcn\/86.5.1563S","article-title":"Homocysteine, vitamins, and vascular disease prevention","volume":"86","author":"McCully","year":"2007","journal-title":"Am J Clin Nutr"},{"issue":"Suppl. 1","key":"10.1016\/j.pharep.2019.01.014_bib0120","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1159\/000328015","article-title":"Microalbuminuria: marker or maker of cardiovascular disease","volume":"119","author":"Abdelhafiz","year":"2011","journal-title":"Nephron Exp Nephrol"},{"key":"10.1016\/j.pharep.2019.01.014_bib0125","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1161\/CIRCOUTCOMES.112.967604","article-title":"Circulating 25-hydroxyvitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies","volume":"5","author":"Wang","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.pharep.2019.01.014_bib0130","first-page":"483","article-title":"Statins: a new insight into their mechanisms of action and consequent pleiotropic effects","volume":"59","author":"Jasi\u0144ska","year":"2007","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.pharep.2019.01.014_bib0135","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1210\/jc.2013-2674","article-title":"Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study","volume":"98","author":"Puurunen","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharep.2019.01.014_bib0140","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2014-000017","article-title":"Statins impair glucose uptake in human cells","volume":"2","author":"Nowis","year":"2014","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.pharep.2019.01.014_bib0145","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0014-5793(01)03007-1","article-title":"Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes","volume":"507","author":"Chamberlain","year":"2001","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharep.2019.01.014_bib0150","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.amjcard.2010.11.023","article-title":"Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia","volume":"107","author":"Krysiak","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharep.2019.01.014_bib0155","first-page":"614","article-title":"Update on the management of polycystic ovary syndrome","volume":"58","author":"Krysiak","year":"2006","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.pharep.2019.01.014_bib0160","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1055\/s-0031-1299765","article-title":"Differential diagnosis of hyperandrogenism in women with polycystic ovary syndrome","volume":"120","author":"Racho\u0144","year":"2012","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.pharep.2019.01.014_bib0165","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1210\/er.2012-1003","article-title":"Cardiometabolic aspects of the polycystic ovary syndrome","volume":"34","author":"Randeva","year":"2012","journal-title":"Endocr Rev"},{"key":"10.1016\/j.pharep.2019.01.014_bib0170","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1530\/EJE-11-0755","article-title":"Recent advances in cardiovascular aspects of polycystic ovary syndrome","volume":"166","author":"Sathyapalan","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.pharep.2019.01.014_bib0175","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/humupd\/dmr001","article-title":"PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis","volume":"17","author":"de Groot","year":"2011","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.pharep.2019.01.014_bib0180","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1210\/jc.2006-1988","article-title":"Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial","volume":"92","author":"Banaszewska","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharep.2019.01.014_bib0185","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1210\/jc.2008-1750","article-title":"The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study","volume":"94","author":"Sathyapalan","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharep.2019.01.014_bib0190","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.fertnstert.2010.11.040","article-title":"Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial","volume":"95","author":"Raja-Khan","year":"2011","journal-title":"Fertil Steril"},{"key":"10.1016\/j.pharep.2019.01.014_bib0195","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1055\/s-0034-1396886","article-title":"Different effects of atorvastatin on metabolic and cardiovascular risk factors in hypercholesterolemic women with normal thyroid function and subclinical hypothyroidism","volume":"123","author":"Krysiak","year":"2015","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.pharep.2019.01.014_bib0200","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1210\/jc.2009-2631","article-title":"Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society Clinical Practice Guideline","volume":"95","author":"Speiser","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharep.2019.01.014_bib0205","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(05)66736-0","article-title":"Congenital adrenal hyperplasia","volume":"365","author":"Merke","year":"2005","journal-title":"Lancet"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114018306613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114018306613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:37:54Z","timestamp":1752611874000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2019.01.014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1734114018306613"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2019.01.014","relation":{},"ISSN":["1734-1140"],"issn-type":[{"type":"print","value":"1734-1140"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of atorvastatin on cardiometabolic risk factors in women with non-classic congenital adrenal hyperplasia: A pilot study","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2019.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}